Table 1.
Clinical and demographic characteristics of patients treated on acute lymphoblastic leukemia protocols, 2012-2017
| Overall | MTX Neurotoxicity | |||
|---|---|---|---|---|
| (n=280) | Yes (n=39) | No (n=241) | p-val. | |
|
|
||||
| Age at Diagnosis, mean(SD) | 8.40 (4.36) | 12.20 (3.27) | 7.79 (4.21) | <0.01 |
| BMI z-score, mean(SD) | 0.23 (1.31) | 0.80 (1.20) | 0.14 (1.31) | <0.01 |
| Patient Sex, n(%) | 0.99 | |||
| Male | 146 (52.1) | 20 (51.3) | 126 (52.3) | |
| Female | 134 (47.9) | 19 (48.7) | 115 (47.7) | |
| Race/Ethnicity, n(%) | <0.01 | |||
| Non-Hispanic White | 100 (36.2) | 8 (20.5) | 92 (38.8) | |
| Hispanic | 133 (48.2) | 29 (74.4) | 104 (43.9) | |
| Non-Hispanic Black | 23 (8.3) | 2 (5.1) | 21 (8.9) | |
| Non-Hispanic Other | 20 (7.3) | 0 (0.0) | 20 (8.4) | |
| Diagnosis, n(%) | 0.28 | |||
| B-ALL | 240 (85.7) | 31 (79.5) | 209 (86.7) | |
| T-ALL | 30 (10.7) | 7 (18.0) | 23 (9.5) | |
| Lymphoblastic Lymphoma | 10 (3.6) | 1 (2.5) | 9 (3.7) | |
| Treatment Arm, n(%) | <0.01 | |||
| Low/Standard Risk | 115 (41.5) | 6 (15.4) | 109 (45.8) | |
| High/Very High Risk | 162 (58.5) | 33 (84.6) | 129 (54.2) | |
| Triple IT Therapy, n(%) | 0.99 | |||
| None | 248 (89.9) | 34 (89.5) | 214 (89.9) | |
| Any | 28 (10.1) | 4 (10.5) | 24 (10.1) | |
| Day 29 MRD, n(%) | 0.11 | |||
| <0.01% | 200 (74.1) | 24 (63.2) | 176 (75.9) | |
| ≥0.01% | 70 (25.9) | 14 (36.8) | 56 (24.1) | |
SD, standard deviation; BMI, body mass index; B-ALL, B-cell acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; IT, intrathecal; MRD, minimal residual disease p-value from t-test for continuous variable or Fisher’s exact test for categorical variables